Effective formulation development strategies for poorly soluble active pharmaceutical ingredients (APIs)

Pharmaceutical Outsourcing

Volumn 12, Issue 2, 2011, Pages 56-61

  Elder, David P ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLODEXTRIN DERIVATIVE; ITRACONAZOLE; SODIUM CHLORIDE; SOLVENT; SURFACTANT;

ARTICLE; CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DESIGN; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; FREEZE DRYING; HYDROPHILICITY; PARTICLE SIZE; SPRAY DRYING; WETTABILITY;

EID: 79954996191     PISSN: 19453337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Lipinski, C.A. Drug-like properties and the causes of poor solubility and permeability, J. Pharmacol. Toxicol Methods, 44: 235-249 (2000).
2. Hauss, D.J. Oral lipid based formulations, Advanced Drug Delivery Reviews, 59: 667-676 (2007).
3. Butler, J.M., Dressman, J.B. The developability classification system: Application of biopharmaceutics concepts to formulation development, J. Pharm. Sci., DOI 10.1002/jps.22217 (2010).
4. Amidon, G.L., Lennernas, H., Shah, V.P., Crison, J.R. A theoretical basis for a biopharmaceutical drug classification: the correlation in vitro drug product dissolution and in vivo bioavailability, Pharmaceutical Research, 12: 413-420 (1995).
5. Noyes, A.A., Whitney, W.R., The rate of solution of a solid substance in their own solutions, J. Am. Chem. Soc., 19; 930 (1897).
6. Serajuddin, A.T.M., Salt formation to improve drug solubility, Adv. Drug Deliv. Revs., 59; 603-616 (2007).
7. Coordination group for mutual recognition - Human committee (CMDh), Request to assess the risk of occurrence of contamination with mesilate esters and other related compounds in pharmaceuticals, EMEA/CMDh/98694/2008, London, 27th February 2008.
8. Remenar, J.F., MacPhee, J.M., Larsen, B.K., Tyagi, V.A., Ho, J.H., McIlror, D.A., Hickey, M.B., Shaw, P.B., Almarsson, O., Salt selection and simultaneous polymorph assessment via high throughput crystallisation: The case of sertraline, Organic Process Research and Development, 7; 990-996 (2003).
9. Kesisoglou, F., Panmai, S., Wu, Y., Nanosizing - Oral formulation development and biopharmaceutical evaluation, Advanced Drug Delivery Reviews, 59; 631-644 (2007).
10. Wu, Y, Loper, A., Landis, L, Hettrick, L, Novak, L., Lynn, K., Chen, C, Thompson, K., Higgins, R., Batra, U., Shelukar, S., Kwei, g., Storey, D., The role of bio-pharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a beagle dog model predicts improved bioavailability and reduced food effect on absorption in humans, Int. J. Pharm., 285; 135-146 (2004).
11. Mosharraf, M., Nystrom, C, The effect of particle size and shape on the surface specific dissolution rate of micronized practically insoluble drugs, Int. J. Pharm., 122; 35-47, (1995).
12. Muller, R.H., Peters, K., Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by a size reduction technique, Int. J. Pharm., 160; 229-237 (1998).
13. Bhat, PA., Dar, A.A., Rather, G.M., Solubilization capabilities of some cationic, anionic, and non-ionic surfactants toward the poorly water soluble antibiotic drug erythromycin, J. Chem. Eng. Data, 53; 1271-1277 (2008).
14. Qiang, D., Gunn, J.A., Schultz, L., Li, Z. J., Evaluation of the impact of sodium lauryl sulphate source variability on solid oral dosage form development, Drug Dev. Ind. Pharm., DOI: 10.3109/03639045.2010.488647 (2010).
15. Joshi, V.Y, Sawant, M.R., Study on dissolution rate enhancement of poorly water soluble drug: Contributions of solubility enhancement and relatively low micelle diffusivity J. Dispers. Sci. Technol., 27; 1141-1150 (2006).
16. Branchu, S., Rogueda, PG., Plumb, A.P., Cook, W.G., A decision support tool for the formulation of orally active, poorly soluble compounds, Eur. J. Pharm. Sci., 32; 128-139.
17. Brewster, M.E., Loftsson, T, Cyclodextrins as pharmaceutical solubilizers, J. Pharm. Sci., 59; 645-666 (2007).
18. Jansook, P., Kurkov, S.V., Loftsson, T, Cycodextrins as solubilizers: Formation of complex aggregates, J. Pharm. Sci.: DOI: 10.1002/jps.21.861 (2010).
19. Mady F.M., Abou-Taleb, A.E., Khaled, K.A., Yamasaki, K., Iohara, D., Ishiguro, T., Hirayama, F., Uekama, K., Otagiri, M., Enhancement of the aqueous solubility and masking the bitter taste of famotidine/SBE-ß-CyD/Povidone K30 Complexation Approach, J. Pharm. Sci., DOI: 10.1002/jps. 22153 (2010).
20. Dahan, A., Miller, J.M., Hoffman, A., Amidon, G.E., Amidon, G.L., The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modelling and application to progesterone, J. Pharm. Sci., DOI: 10.1002/jps.22033 (2009).
21. O'Driscoll, CM., Griffin, B.T., Biopharmaceutical challenges associated with drugs with low aqueous solubility - The potential impact of lipid-based formulations, Advanced Drug Delivery Reviews, 60; 617-624 (2008).
22. Singh, B.N., A quantitative approach to probe the dependence and correlation of food-effect with aqueous solubility, dose/solubility ratio, and partition coefficient (log P) for orally active drugs administered as immediate release formulations, Drug Dev. Res., 65; 55-75 (2005).
23. Porter, C.J.H., Pouton, C.W., Cuine, J.F., Charman, W.M., Enhancing intestinal drug solubilisation using lipid-based delivery systems, Advanced Drug Delivery Reviews 60; 673-691 (2008).
24. Gullapalli, R.P., Soft gelatin capsules (softgels), J. Pharm. Sci., DOI: 10.1002/jps.22151 (2010).
25. Carstensen, J.T., Morris, T.,Chemical stability of indomethacin in the solid amorphous and molten states,J. Pharm. Sci., 82; 657 (1993).
26. Breitenbach, J., Melt extrusion: from process to drug delivery, Eur. J. Pharm. Biopharm., 54; 107-117 (2002).
27. Shoyele, S.A., Cawthorne, S., Particle engineering techniques for inhaled biopharmaceuticals, Advanced Drug Delivery Reviews, 58; 1009-1029 (2006).
28. DiNunzio, J.C., Miller, D.A., Yang, W., McGinty, J.W., Williams, R.O., Amorphous compositions using concentrating enhancing polymers for improved bioavailability of itraconazole, Mol. Pharm., 5; 968-980 (2008).